Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market

Wellgistics Health, Inc.

Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.
GLP-1 agonist market forecast to grow from $70B (2025) to $201B (2030) per Grandview Research.
Forzet has been evaluated in multiple controlled clinical studies (Type 2 diabetes, heart failure, COPD) in Europe.
Product is classified as medical food, not FDA-approved drug; available OTC under physician supervision.
Initial availability through Wellgistics affiliated pharmacy and select network pharmacies; no revenue guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.